Sleep disorders include a variety of complications related to sleep and have a high prevalence across the globe. Based on these complications, sleep disorders can be classified into three categories- lack of sleep which includes insomnia, excessive sleep which includes narcolepsy and disturbed sleep which include sleep apnea and Rapid eye movement (REM) disorder. Insomnia may arise as result of unhealthy diet, emotional dreams, stress, and many other factors.

Insomnia may affect reaction time towards common stimulus, hand-eye coordination, memory, and disturb daily life. Narcolepsy is a disorder that causes uncontrolled sleep at time period lasting less than minute or more than an hour. It has also been found that patients with narcolepsy experience sleep attacks more often during pregnancy, stress or ill health.

Request For Report Sample@ https://www.persistencemarketresearch.com/samples/5714

Usually narcolepsy is a genetic disease, but it has also been found to develop as a result of some neurological disorders or severe brain damage. REM sleep behavior disorder involves abnormal behavior in sleep. In this disorder, a patient dreaming about running, may run while still asleep. Sleep apnea is obstructed breathing during sleep.

According to a press release in March 2014 by World Association of Sleep Medicine, 45% of the global population suffers from some form of sleep disorder. It also mentions that approximately 25% male and 10% females in the U.S. suffer from sleep apnea. This high prevalence suggests an opportunity for a large therapeutics market.

Currently marketed drugs include Sanofi-Aventis manufactured Ambien (zolpidem), Sunovion Pharmaceuticals Inc.’s Lunesta (eszopiclone), Takeda Pharmaceutical’s Rozerem (ramelteon), Somaxon Pharmaceuticals, Inc.’s Silenor (doxepine) and various others. Over-the-counter drugs are also available for treating sleep disorder; these include

Nytol,
Sominex,
Compoz, and
Unisom.

Merck’s Suvorexant drug is an orexin receptor agonist which is under Phase III trial. Other companies involved in the drug development of sleep disorder include

Vanda Pharmaceuticals,
Eli Lilly,
GlaxoSmithKline and
Neurim Pharmaceuticals.

Request For Report Table of Content (TOC)@ https://www.persistencemarketresearch.com/toc/5714

Key geographies evaluated in this report are:

North America
U.S
Canada
Europe
France, Germany, Italy, Spain, and the UK
Eastern Europe
CIS
APAC
China
India
Japan
Australia
Others
Latin America
Argentina
Brazil
Others

Key features of this report

Drivers, restraints, and challenges shaping the Sleep Disorder Therapeutics market dynamics
Latest innovations and key events in the industry
Analysis of business strategies of the top players
Sleep Disorder Therapeutics market estimates and forecasts(2015 -2021)

Know More About Report@ https://www.persistencemarketresearch.com/market-research/sleep-disorder-therapeutics-market.asp